236 related articles for article (PubMed ID: 28099487)
1. Metabolic Imaging of Head and Neck Cancer Organoids.
Shah AT; Heaster TM; Skala MC
PLoS One; 2017; 12(1):e0170415. PubMed ID: 28099487
[TBL] [Abstract][Full Text] [Related]
2. Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma.
Shah AT; Demory Beckler M; Walsh AJ; Jones WP; Pohlmann PR; Skala MC
PLoS One; 2014; 9(3):e90746. PubMed ID: 24595244
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
4. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
[TBL] [Abstract][Full Text] [Related]
5. Head and neck squamous cell cancer (stages III and IV) induction chemotherapy assessment: value of FDG volumetric imaging parameters.
Yu J; Cooley T; Truong MT; Mercier G; Subramaniam RM
J Med Imaging Radiat Oncol; 2014 Feb; 58(1):18-24. PubMed ID: 24529051
[TBL] [Abstract][Full Text] [Related]
6. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response.
Walsh AJ; Castellanos JA; Nagathihalli NS; Merchant NB; Skala MC
Pancreas; 2016 Jul; 45(6):863-9. PubMed ID: 26495796
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived head and neck cancer organoids allow treatment stratification and serve as a tool for biomarker validation and identification.
Millen R; De Kort WWB; Koomen M; van Son GJF; Gobits R; Penning de Vries B; Begthel H; Zandvliet M; Doornaert P; Raaijmakers CPJ; Geurts MH; Elias SG; van Es RJJ; de Bree R; Devriese LA; Willems SM; Kranenburg O; Driehuis E; Clevers H
Med; 2023 May; 4(5):290-310.e12. PubMed ID: 37178682
[TBL] [Abstract][Full Text] [Related]
9. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment.
Shah AT; Diggins KE; Walsh AJ; Irish JM; Skala MC
Neoplasia; 2015 Dec; 17(12):862-870. PubMed ID: 26696368
[TBL] [Abstract][Full Text] [Related]
11. Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids.
Sharick JT; Jeffery JJ; Karim MR; Walsh CM; Esbona K; Cook RS; Skala MC
Neoplasia; 2019 Jun; 21(6):615-626. PubMed ID: 31078067
[TBL] [Abstract][Full Text] [Related]
12. Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: results of in vitro and in vivo studies.
Barnea I; Haif S; Keshet R; Karaush V; Lev-Ari S; Khafif A; Shtabsky A; Yarden Y; Vexler A; Ben Yosef R
Head Neck; 2013 Mar; 35(3):399-407. PubMed ID: 22367849
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of optical imaging agents in a fluorescence-guided surgical model of head and neck cancer.
Prince AC; Moore LS; Tipirneni KE; Ramesh T; Limdi MA; Bevans SL; Walsh EM; Greene B; Rosenthal EL; Warram JM
Surg Oncol; 2018 Jun; 27(2):225-230. PubMed ID: 29937175
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
Ansell A; Jedlinski A; Johansson AC; Roberg K
J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
[TBL] [Abstract][Full Text] [Related]
15. Functional Optical Imaging of Primary Human Tumor Organoids: Development of a Personalized Drug Screen.
Walsh AJ; Cook RS; Skala MC
J Nucl Med; 2017 Sep; 58(9):1367-1372. PubMed ID: 28588148
[TBL] [Abstract][Full Text] [Related]
16. Targeting serum glucocorticoid-regulated kinase-1 in squamous cell carcinoma of the head and neck: a novel modality of local control.
Berdel HO; Yin H; Liu JY; Grochowska K; Middleton C; Yanasak N; Abdelsayed R; Berdel WE; Mozaffari M; Yu JC; Baban B
PLoS One; 2014; 9(12):e113795. PubMed ID: 25485633
[TBL] [Abstract][Full Text] [Related]
17. Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Klinghammer K; Otto R; Raguse JD; Albers AE; Tinhofer I; Fichtner I; Leser U; Keilholz U; Hoffmann J
Int J Cancer; 2017 Sep; 141(6):1215-1221. PubMed ID: 28560858
[TBL] [Abstract][Full Text] [Related]
18. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
[TBL] [Abstract][Full Text] [Related]
19. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.
Walsh AJ; Cook RS; Sanders ME; Aurisicchio L; Ciliberto G; Arteaga CL; Skala MC
Cancer Res; 2014 Sep; 74(18):5184-94. PubMed ID: 25100563
[TBL] [Abstract][Full Text] [Related]
20. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
